AR045819A1 - Derivados de benzimidazol composiciones que los contienen, preparacion de los mismos y usos de los mismos - Google Patents
Derivados de benzimidazol composiciones que los contienen, preparacion de los mismos y usos de los mismosInfo
- Publication number
- AR045819A1 AR045819A1 ARP040103467A ARP040103467A AR045819A1 AR 045819 A1 AR045819 A1 AR 045819A1 AR P040103467 A ARP040103467 A AR P040103467A AR P040103467 A ARP040103467 A AR P040103467A AR 045819 A1 AR045819 A1 AR 045819A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- aryl
- heterocyclyl
- cycloalkenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a compuestos de que son útiles en terapia, en particular para el tratamiento del dolor. Reivindicación 1: Un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, en la cual: R1 está seleccionado entre alquilo C1-10, alquenilo C2-10, alquinilo C2-10, R5R6N-alquilo C1-6, R5O-alquilo C1-6, R5C(=O)N(-R6)-alquilo C1-6, R5R6NS(=O)2-alquilo C1-6, R5CS(=O)2N(-R6)-alquilo C1-6, R5R6NC(=O)N(-R7)-alquilo C1-6, R5R6NS(=O)2N(R7)-alquilo C1-6, arilo(C6-10)- alquilo(C1-6), arilo(C6-10)-C(=O)-alquilo C1-6, cicloalquilo(C3-10)-alquilo(C1-6), cicloalquenilo(C4-8)-alquilo(C1-6), heterociclilo(C3-6)-alquilo(C1-6), heterociclilo(C3-6)-C(=O)-alquilo C1-6, hidrocarbilamino C1-10, R5R6N-, R5O-, R5C(=O)N(-R6)-, R5R6NS(=O)2-, R5CS(=O)2N(-R6)-, R5R6NC(=O)N(-R7)-, R5R6NS(=O)2N(R7)-, arilo C6-10, arilo(C6-10)-C(=O)-, cicloalquilo C3-10, cicloalquenilo C4-8, heterociclilo C3-6 y heterociclilo(C3-6)-C(=O)-; donde dicho alquilo C1-10, alquenilo C2-10, alquinilo C2-10, arilo(C6-10)-alquilo(C1-6), arilo(C6-10)-C(=O)-alquilo C1-6, cicloalquilo(C3-10)-alquilo(C1-6), cicloalquenilo(C4-8)-alquilo(C1-6), heterociclilo(C3-6)-alquilo(C1-6), heterociclilo(C3-6)-C(=O)-alquilo C1-6, hidrocarbilamino (C1-10), arilo C6- 10, arilo(C6-10)-C(=O)-, cicloalquilo C3-10, cicloalquenilo C4-8, heterociclilo C3-6 o heterociclilo(C3-6)-C(=O)- usados en la definición de R1 están opcionalmente sustituido con uno o más grupos seleccionados entre halógeno, ciano, nitro, metoxi, etoxi, metilo, etilo, hidroxi y -NR5R6; R2 está seleccionado entre alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-10, cicloalquilo(C3-10)-alquilo(C1-6), cicloalquenilo(C4-8)-alquilo(C1-6), heterocicloalquilo(C3-6)-alquilo(C1-6), cicloalquenilo C4-8, R5R6N-, heteroarilo C3-5, arilo C6-10 y heterocicloalquilo C3-6, donde dicho alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-8, cicloalquilo(C3-8)-alquilo(C1-6), cicloalquenilo(C4-8)-alquilo(C1-6), heterocicloalquilo(C3-6)-alquilo(C1-6), cicloalquenilo C4-8, heteroarilo C3-5, arilo C6-10 o heterocicloalquilo C3-6, usados en la definición de R2 están opcionalmente sustituido con uno o más grupos seleccionados entre halógeno, ciano, nitro, metoxi, etoxi, metilo, etilo, hidroxi y -NR5R6; donde R5, R6 y R7 están independientemente seleccionados entre -H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6 y un grupo C1-6 divalente que conjuntamente con otro R5, R6 o R7 divalente forma una porción de un anillo; R3 está seleccionado entre -H, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-10, cicloalquilo(C3-10)-alquilo(C1-6), cicloalquenilo(C4-8)-alquilo(C1-6), heterocicloalquilo C3-6, o un grupo de fórmulas (2), opcionalmente sustituidos con uno o más grupos seleccionados entre alquilo C1-6, halógeno, amino y alcoxi C1-6; cada uno de R8 y R9 está independientemente seleccionado entre -H, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-10, cicloalquilo(C3-10)-alquilo(C1-6), heterociclilo C3-6, arilo C6-10, heterociclilo(C3-6)-alquilo(C1-6), arilo(C6-10)-alquilo(C1-6) y un grupo C1-6 divalente que conjuntamente con otro grupo divalente seleccionado entre R8 y R9 forma una porción de un anillo, donde dicho alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-10, cicloalquilo(C3-10)-alquilo(C1-6), heterociclilo C3-6, arilo C6-10, heterociclilo(C3-6)-alquilo(C1-6), arilo(C6-10)-alquilo(C1-6) o un grupo C1-6 divalente está opcionalmente sustituido con uno o más grupos seleccionados entre halógeno, ciano, nitro, metoxi, etoxi, metilo, etilo, hidroxi y -NR5R6; y R4 está seleccionado entre -H, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-10, cicloalquilo(C3-10)-alquilo(C1-6) y cicloalquenilo(C4-8)-alquilo(C1-6).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0302573A SE0302573D0 (sv) | 2003-09-26 | 2003-09-26 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045819A1 true AR045819A1 (es) | 2005-11-16 |
Family
ID=29246982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103467A AR045819A1 (es) | 2003-09-26 | 2004-09-24 | Derivados de benzimidazol composiciones que los contienen, preparacion de los mismos y usos de los mismos |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US8633235B2 (es) |
| EP (1) | EP1670769B1 (es) |
| JP (1) | JP4896721B2 (es) |
| KR (1) | KR101170184B1 (es) |
| CN (2) | CN102010373A (es) |
| AR (1) | AR045819A1 (es) |
| AT (1) | ATE430135T1 (es) |
| AU (1) | AU2004276062B2 (es) |
| BR (1) | BRPI0414780B8 (es) |
| CA (1) | CA2539738C (es) |
| CO (1) | CO5680443A2 (es) |
| CY (1) | CY1110332T1 (es) |
| DE (1) | DE602004020907D1 (es) |
| DK (1) | DK1670769T3 (es) |
| ES (1) | ES2324669T3 (es) |
| HK (1) | HK1089436A1 (es) |
| HR (1) | HRP20090388T1 (es) |
| IL (1) | IL174215A0 (es) |
| IS (1) | IS8422A (es) |
| MX (1) | MXPA06003197A (es) |
| MY (1) | MY140630A (es) |
| NO (1) | NO20061839L (es) |
| NZ (1) | NZ545736A (es) |
| PL (1) | PL1670769T3 (es) |
| PT (1) | PT1670769E (es) |
| RU (1) | RU2346938C2 (es) |
| SA (1) | SA04250310B1 (es) |
| SE (1) | SE0302573D0 (es) |
| SI (1) | SI1670769T1 (es) |
| TW (1) | TW200521117A (es) |
| UA (1) | UA86776C2 (es) |
| UY (1) | UY28536A1 (es) |
| WO (1) | WO2005030732A1 (es) |
| ZA (3) | ZA200602446B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2294330T3 (es) | 2002-08-02 | 2008-04-01 | MERCK & CO., INC. | Derivados de furo(2,3-b)piridina sustituidos. |
| SE0302573D0 (sv) | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| EP1797077B1 (en) * | 2004-09-24 | 2012-02-15 | AstraZeneca AB | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i |
| JP2008514592A (ja) * | 2004-09-24 | 2008-05-08 | アストラゼネカ・アクチエボラーグ | ベンゾイミダゾール誘導体、それらを含有する組成物、それらの製造及びそれらの使用ｉｉｉ |
| CN101031563A (zh) * | 2004-09-24 | 2007-09-05 | 阿斯利康(瑞典)有限公司 | 苯并咪唑衍生物、含有它们的组合物、其制备方法和用途 |
| MX2007003105A (es) | 2004-09-24 | 2007-06-07 | Aztrazeneca Ab | Derivados de bencimidazol, composiciones que los contienen, sus preparaciones y sus usos i. |
| CA2586179C (en) | 2004-11-02 | 2011-02-08 | Pfizer Inc. | Sulfonyl benzimidazole derivatives |
| CN101233098A (zh) * | 2005-07-29 | 2008-07-30 | 阿斯利康(瑞典)有限公司 | 成对((二氟环烷基)甲基)胺的制备方法 |
| TW200745049A (en) * | 2006-03-23 | 2007-12-16 | Astrazeneca Ab | New crystalline forms |
| TW200808769A (en) * | 2006-04-18 | 2008-02-16 | Astrazeneca Ab | Therapeutic compounds |
| US20080139846A1 (en) * | 2006-09-01 | 2008-06-12 | Astrazeneca Ab | New Process 298 |
| WO2008032764A1 (fr) * | 2006-09-13 | 2008-03-20 | Kyowa Hakko Kirin Co., Ltd. | Dérivé hétérocyclique fusionné |
| US20110086853A1 (en) * | 2009-10-08 | 2011-04-14 | William Brown | Therapeutic Compounds |
| RU2454234C1 (ru) * | 2011-03-16 | 2012-06-27 | Константин Михайлович Аверин | Соли 1,3-диэтилбензимидазолия - иммуностимулирующие средства и фармацевтические композиции на их основе |
| UA119740C2 (uk) * | 2012-06-13 | 2019-08-12 | Сайтек Текнолоджи Корп. | Композиції стабілізатора, що містять заміщені хроманові сполуки, і способи застосування |
| ME02590B (me) | 2012-06-26 | 2017-06-20 | Bayer Pharma AG | N- [4-(hinolin-4-iloksi)cikloheksil(metil)] (hetero)arilkarboksamidi kao antagonisti androgenog receptora, njihova proizvodnja i upotreba kao medicinski produkti |
| WO2019170543A1 (en) | 2018-03-07 | 2019-09-12 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
| EP3972963A1 (en) | 2019-05-21 | 2022-03-30 | Bayer Aktiengesellschaft | Identification and use of kras inhibitors |
| CN112010789A (zh) * | 2019-05-31 | 2020-12-01 | 中国科学院上海药物研究所 | 乙烯基磺酰胺或乙烯基酰胺类化合物及其制备方法和用途 |
| KR20230131133A (ko) * | 2022-03-04 | 2023-09-12 | 삼진제약주식회사 | 신규한 헤테로 고리 화합물 및 이를 포함하는 약학적 조성물 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1604908A (en) | 1965-06-24 | 1971-05-15 | Substd benzimidazoles - with anthelmintic,fungicidal activity and some with antiviral and antibacterial activity | |
| FR5354M (es) | 1965-09-10 | 1967-09-11 | ||
| US5387600A (en) | 1992-07-30 | 1995-02-07 | Fuji Photo Film Co., Ltd. | Treating arteriosclerosis using benzimidazole compositions |
| DE4237557A1 (de) | 1992-11-06 | 1994-05-11 | Bayer Ag | Substituierte Benzimidazole |
| DE4237597A1 (de) | 1992-11-06 | 1994-05-11 | Bayer Ag | Substituierte Benzimidazole |
| DE4237617A1 (de) * | 1992-11-06 | 1994-05-11 | Bayer Ag | Verwendung von substituierten Benzimidazolen |
| AU722514B2 (en) * | 1995-12-28 | 2000-08-03 | Fujisawa Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| US6348032B1 (en) * | 1998-11-23 | 2002-02-19 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with benzimidazole derivatives |
| WO2001012600A1 (en) | 1999-08-12 | 2001-02-22 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
| US6844367B1 (en) * | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| US6632815B2 (en) * | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| CA2385589A1 (en) | 1999-09-17 | 2001-03-22 | Bing-Yan Zhu | Inhibitors of factor xa |
| US6720317B1 (en) * | 1999-09-17 | 2004-04-13 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| US7115645B2 (en) * | 2000-01-14 | 2006-10-03 | Schering Aktiengesellschaft | 1,2 diarylbenzimidazoles and their pharmaceutical use |
| TWI287005B (en) * | 2000-01-14 | 2007-09-21 | Schering Ag | 1,2-diaylbenzimidazoles and their pharmaceutical use |
| US7329679B2 (en) * | 2000-01-27 | 2008-02-12 | Schering Aktiengesellschaft | 1,2 Diarylbenzimidazoles and their pharmaceutical use |
| WO2001064643A2 (en) * | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| WO2002046168A1 (en) | 2000-12-07 | 2002-06-13 | Astrazeneca Ab | Therapeutic benzimidazole compounds |
| SE0101387D0 (sv) * | 2001-04-20 | 2001-04-20 | Astrazeneca Ab | Novel compounds |
| US7199147B2 (en) | 2001-06-12 | 2007-04-03 | Dainippon Sumitomo Pharma Co., Ltd. | Rho kinase inhibitors |
| AR043633A1 (es) | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
| SE0301699D0 (sv) * | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| SE0301701D0 (sv) | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| WO2005007625A2 (en) | 2003-07-14 | 2005-01-27 | The University Of Tennessee Research Foundation | Heterocyclic amides with anti-tuberculosis activity |
| WO2005021547A2 (en) | 2003-08-28 | 2005-03-10 | Pharmaxis Pty Ltd. | Heterocyclic cannabinoid cb2 receptor antagonists |
| SE0302570D0 (sv) | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| SE0302571D0 (sv) | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| SE0302572D0 (sv) | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| SE0302573D0 (sv) | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| CA2567343A1 (en) | 2004-05-20 | 2005-12-01 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
| WO2006009876A2 (en) | 2004-06-17 | 2006-01-26 | Cengent Therapeutics, Inc. | Trisubstituted nitrogen modulators of tyrosine phosphatases |
| ES2697524T3 (es) | 2004-07-30 | 2019-01-24 | Exelixis Inc | Derivados de pirrol como agentes farmacéuticos |
| US20060052421A1 (en) * | 2004-09-09 | 2006-03-09 | Eastman Kodak Company | Conjugation agent |
| JP2008514592A (ja) | 2004-09-24 | 2008-05-08 | アストラゼネカ・アクチエボラーグ | ベンゾイミダゾール誘導体、それらを含有する組成物、それらの製造及びそれらの使用ｉｉｉ |
| EP1797077B1 (en) | 2004-09-24 | 2012-02-15 | AstraZeneca AB | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i |
| CA2582512A1 (en) | 2004-09-24 | 2006-03-30 | Astrazeneca Ab | Compounds, compositions containing them, preparations thereof and uses thereof ii |
| EP1797074A4 (en) | 2004-09-24 | 2009-04-01 | Astrazeneca Ab | COMPOUNDS, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND APPLICATIONS THEREOF IIII |
| EP1794150A1 (en) | 2004-09-24 | 2007-06-13 | AstraZeneca AB | Benzimidazole derivatives and their use as cannabinoid receptor ligands I |
| MX2007003105A (es) * | 2004-09-24 | 2007-06-07 | Aztrazeneca Ab | Derivados de bencimidazol, composiciones que los contienen, sus preparaciones y sus usos i. |
| WO2006033629A1 (en) | 2004-09-24 | 2006-03-30 | Astrazeneca Ab | Benzimidazole derivatives and their use as cannabinoid receptor ligands |
| WO2006033628A1 (en) | 2004-09-24 | 2006-03-30 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| CA2586179C (en) * | 2004-11-02 | 2011-02-08 | Pfizer Inc. | Sulfonyl benzimidazole derivatives |
| WO2006078941A2 (en) | 2005-01-20 | 2006-07-27 | Sirtris Pharmaceuticals, Inc. | Novel sirtuin activating compounds and methods of use thereof |
| TW200745049A (en) | 2006-03-23 | 2007-12-16 | Astrazeneca Ab | New crystalline forms |
| TW200808769A (en) * | 2006-04-18 | 2008-02-16 | Astrazeneca Ab | Therapeutic compounds |
| TW200808772A (en) * | 2006-06-13 | 2008-02-16 | Astrazeneca Ab | Therapeutic compounds |
-
2003
- 2003-09-26 SE SE0302573A patent/SE0302573D0/xx unknown
-
2004
- 2004-09-24 PL PL04768667T patent/PL1670769T3/pl unknown
- 2004-09-24 TW TW093129150A patent/TW200521117A/zh unknown
- 2004-09-24 CN CN2010105277900A patent/CN102010373A/zh active Pending
- 2004-09-24 WO PCT/GB2004/004124 patent/WO2005030732A1/en active Application Filing
- 2004-09-24 AU AU2004276062A patent/AU2004276062B2/en active Active
- 2004-09-24 DE DE602004020907T patent/DE602004020907D1/de not_active Expired - Lifetime
- 2004-09-24 RU RU2006113371/04A patent/RU2346938C2/ru active
- 2004-09-24 NZ NZ545736A patent/NZ545736A/en unknown
- 2004-09-24 SI SI200431166T patent/SI1670769T1/sl unknown
- 2004-09-24 ES ES04768667T patent/ES2324669T3/es not_active Expired - Lifetime
- 2004-09-24 MY MYPI20043910A patent/MY140630A/en unknown
- 2004-09-24 AR ARP040103467A patent/AR045819A1/es not_active Application Discontinuation
- 2004-09-24 DK DK04768667T patent/DK1670769T3/da active
- 2004-09-24 CN CNA2004800350086A patent/CN1886379A/zh active Pending
- 2004-09-24 JP JP2006527490A patent/JP4896721B2/ja not_active Expired - Lifetime
- 2004-09-24 PT PT04768667T patent/PT1670769E/pt unknown
- 2004-09-24 CA CA2539738A patent/CA2539738C/en not_active Expired - Lifetime
- 2004-09-24 MX MXPA06003197A patent/MXPA06003197A/es active IP Right Grant
- 2004-09-24 UY UY28536A patent/UY28536A1/es unknown
- 2004-09-24 UA UAA200602693A patent/UA86776C2/ru unknown
- 2004-09-24 AT AT04768667T patent/ATE430135T1/de active
- 2004-09-24 EP EP04768667A patent/EP1670769B1/en not_active Expired - Lifetime
- 2004-09-24 BR BRPI0414780A patent/BRPI0414780B8/pt active IP Right Grant
- 2004-09-24 KR KR1020067005825A patent/KR101170184B1/ko active IP Right Grant
- 2004-09-24 US US10/573,054 patent/US8633235B2/en active Active
- 2004-09-26 SA SA04250310A patent/SA04250310B1/ar unknown
-
2006
- 2006-03-09 IL IL174215A patent/IL174215A0/en unknown
- 2006-03-22 CO CO06028452A patent/CO5680443A2/es not_active Application Discontinuation
- 2006-03-24 ZA ZA200602446A patent/ZA200602446B/en unknown
- 2006-04-21 IS IS8422A patent/IS8422A/is unknown
- 2006-04-26 NO NO20061839A patent/NO20061839L/no not_active Application Discontinuation
- 2006-09-01 HK HK06109758.7A patent/HK1089436A1/xx not_active IP Right Cessation
-
2007
- 2007-03-13 ZA ZA200702131A patent/ZA200702131B/xx unknown
- 2007-03-16 ZA ZA200702226A patent/ZA200702226B/xx unknown
-
2009
- 2009-07-07 HR HR20090388T patent/HRP20090388T1/xx unknown
- 2009-07-08 CY CY20091100725T patent/CY1110332T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045819A1 (es) | Derivados de benzimidazol composiciones que los contienen, preparacion de los mismos y usos de los mismos | |
| AR044666A1 (es) | Derivados benzoimidazolicos, composiciones que los contienen, su preparacion y usos de los mismos. | |
| CO5660261A2 (es) | Derivados de bencimidazol, composiciones que los contienen, preparacion de estos y usos de estos | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| AR049898A1 (es) | Compuestos aminocarbonil fenilo sustituidos, composicion farmaceutica,uso y proceso para prepararlos | |
| AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
| PE20231312A1 (es) | Derivados triciclicos de carboxamida como inhibidores de la prmt5 | |
| AR045822A1 (es) | Derivados de bencimidazol, composiciones que los contienen preparacion de los mismos y usos de los mismos | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR042956A1 (es) | Inhibidores de girasa y usos de los mismos | |
| AR070343A1 (es) | Piridinil amidas, un procedimiento para el tratamiento de la esquizofrenia en un mamifero y una composicion farmaceutica | |
| PE20091095A1 (es) | Moduladores de gamma secretasa | |
| AR054481A1 (es) | Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol | |
| AR035667A1 (es) | Imidazo[4,5-c]quinolin-4-aminas y tetrahidroimidazo[4,5-c]quinolin-4-aminas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos | |
| ECSP099706A (es) | Nuevos derivados de n-(8-heteroariltetrahidronaftalen-2yl) y n-(5-heteroarilcroman-3-il) carboxamida para el tratamiento del dolor | |
| AR035543A1 (es) | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| PE20081689A1 (es) | Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas y su preparacion | |
| AR044543A1 (es) | Derivados de pirazolo-quinazolina, un procedimiento para su preparacion y su uso como inhibidor de quinasa | |
| AR035812A1 (es) | Compuestos de acrilamida farmaceuticamente efectivos como inhibidores de la enoil-acp reductasa-fabi-; composiciones formuladas con dichos compuestos, metodo para inhibir dicha reductasa , respectivamente, para tratar infecciones bacterianas utilizando dichos compuestos y uso de los compuestos menci | |
| AR077463A1 (es) | Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias | |
| AR060472A1 (es) | Derivados de sulfonil-benzimidazoles moduladores o ligandos de receptores cb1, composiciones farmaceuticas que los contienen, metodo de preparacion y usos en terapia, particularmente para alivio del dolor. | |
| CO5590916A2 (es) | Dicetopiperacinas sustituidas como antagonistas de oxitocina | |
| AR074353A1 (es) | Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatititis atopica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |